He is currently the lead investigator in a groundbreaking phase II transarterial chemoperfusion clinical trial for patients with unresectable pleural mesothelioma.
It involves identifying specific blood vessels that feed the tumors, then overloading those vessels with high doses of specific chemotherapy agents to stop the cancer growth without exposing the rest of the body.
He is heavily involved with image guided tumor therapy, image-guided biopsies and urinary and biliary interventions, arterial and venous stenting. He also does minimally invasive percutaneous tumor ablation.
Kis came to Moffitt after completing radiology residency and interventional radiology fellowship at Brigham and Women’s Hospital, Harvard Medical School in Boston.
In 2020, Kis presented a novel mesothelioma treatment at the Society of Interventional Radiology’s Annual Scientific Meeting. He discussed the potential of transarterial chemoperfusion with cisplatin, methotrexate, and gemcitabine every four weeks as a feasible and safe treatment for patients with relapsed unresectable malignant pleural mesothelioma.
Dr. Kis’s clinical study of this new treatment resulted in a 70.3% disease control rate for patients with a median overall survival rate of 8.5 months. Patients reported that they tolerated the treatment well and that side effects were relatively minor such as mild nausea and chest pain.
“We were pleasantly surprised to find that this treatment doesn’t come with the same side effects of traditional intravenous chemotherapy,” said Kis during the virtual session. “To see these promising results with so few side effects means we are able to make a positive impact on quality of life for these patients.”
He holds a doctorate in cerebral microcirculation from University of Szeged in Hungary and did a post-doctoral fellowship and surgery internship at Wake Forest University Baptist Medical Center in Winston-Salem, North Carolina.